SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Preventive Visit — Ada Lovelace — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientAda Lovelace
Date of birth1815-12-10
IdentifiersMRN HR-NI031-SYN-TD; SSN (made up) 000-31-6729
Document date1851-08-18
AuthorConstance Whitley-Adeyemi, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Periodic adult preventive visit. [S]

History of Present Illness

Mrs. Lovelace is a 35-year-old mathematician with stage IVB adenocarcinoma of the cervix, on carboplatin, paclitaxel and pembrolizumab, who comes for a preventive visit. She had her third cycle a week ago. There has been no bleeding since the pelvic radiation. Her average pelvic pain is about 3 of 10 on long-acting morphine 15 mg twice a day, with one or two breakthrough doses on some days, and she is not drowsy in the mornings. Her bowels open every day or two since the laxatives were increased. She has mild tingling in her toes. She is working on her mathematics most mornings. She would like her vaccinations brought up to date while she is on treatment, and to set down her wishes. [S]

ElementDetail
VisitPeriodic adult preventive visit, age 35
TreatmentThree cycles of carboplatin, paclitaxel and pembrolizumab
PainAbout 3 of 10 on long-acting morphine; no morning drowsiness
BowelsOpening every day or two
MoodPHQ-2 2

Health risk assessment. Completed by the patient on paper in the waiting room and reviewed with her face to face by Dr. Whitley-Adeyemi. [S]

DomainFinding
Self-rated healthFair; better than in the spring
PsychosocialWorried about her debts and about her family; supported at home
TobaccoNever
AlcoholNone since diagnosis; AUDIT-C 0
GamblingHas stopped betting since her diagnosis; would like help with the debts
Physical activityShort walks most days
NutritionAppetite fair; weight steady
SleepSeven hours, broken on the nights after chemotherapy
SafetyFeels safe at home; morphine kept in a locked box; naloxone at home
Sexual healthNot sexually active since the bleeding began
Activities of daily livingIndependent
Hearing and visionNo concerns

Review of Systems

SystemResultFinding
ConstitutionalPositiveTiredness for a few days after each cycle; no fever or night sweats
EyesNegativeNo change in vision
Ears, nose, mouth, and throatNegativeNo mouth ulcers
CardiovascularNegativeNo chest pain or leg swelling
RespiratoryNegativeNo cough or breathlessness
GastrointestinalNegativeBowels regular on laxatives; mild nausea for two days after each cycle
GenitourinaryNegativeNo vaginal bleeding since radiation; light discharge; no urinary symptoms
MusculoskeletalNegativeNo joint pain
IntegumentaryPositiveHair thinning on chemotherapy; no rash
NeurologicalPositiveMild tingling in the toes, not affecting walking
EndocrineNegativeNo heat or cold intolerance
PsychiatricNegativeMood fair; PHQ-2 score 2

12 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Opium tincture (100 mg/mL opium, equivalent to 10 mg/mL morphine), 0.5 mL by mouth four to six times a day as needed for pain0.5 mL four to six times a day as neededOral route1849-06-03 to 1851-06-02completedS
Morphine sulfate oral solution 2 mg/mL, 5 mg (2.5 mL by oral syringe) every 4 hours as needed for pain5 mg every 4 hours as neededOral route1851-06-02activeS
Morphine sulfate extended-release 15 mg tablet, one tablet by mouth every 12 hours; swallow wholeevery 12 hoursOral route1851-06-16 to 1851-10-20completedS
Naloxone 4 mg nasal spray, one spray in a nostril for suspected opioid overdose; call 911one spray as needed for suspected overdose; repeat after 2 to 3 minutes if neededNasal route1851-06-02activeS
Senna 8.6 mg tablet, two tablets by mouth at nighttwo tablets at nightOral route1851-06-02activeS
Polyethylene glycol 3350, 17 g in water by mouth once or twice a dayonce daily, up to twice dailyOral route1851-06-02activeS
Acetaminophen 500 mg tablet, two tablets by mouth three times a day1 g three times a dayOral route1851-06-02activeS
Ferric carboxymaltose 750 mg intravenous infusion, two doses at the first two visits750 mg on two occasions two weeks apartIntravenous route1851-06-02 to 1851-06-17completedS
Pembrolizumab 200 mg intravenously every 3 weeksevery 3 weeksIntravenous route1851-06-30activeS
Carboplatin, dose to an AUC of 5 (650 mg), intravenously every 3 weeks for six cyclesevery 3 weeks for six cyclesIntravenous route1851-06-30 to 1851-10-13completedS
Paclitaxel 175 mg/m2 (275 mg) intravenously every 3 weeks for six cycles, with premedicationevery 3 weeks for six cyclesIntravenous route1851-06-30 to 1851-10-13completedS
Ondansetron 8 mg tablet, one tablet by mouth twice a day for three days after each chemotherapy cycle, then as neededtwice a day for three days after each cycle, then as neededOral route1851-06-30activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1851-08-18Body height165cmS
1851-08-18Body weight53.6kgS
1851-08-18Body mass index (BMI) [Ratio]19.7kg/m2S
1851-08-18Systolic blood pressure110mm[Hg]S
1851-08-18Diastolic blood pressure70mm[Hg]S
1851-08-18Heart rate80/minS
1851-08-18Respiratory rate16/minS
1851-08-18Body temperature36.6CelS
1851-08-18Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1851-08-18Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]2{score}S

Physical Exam

Vital signs recorded on 1851-08-18; see the Vital Signs section. [S]

SystemFinding
ConstitutionalSlender, alert; weight 53.6 kg, BMI 19.7; blood pressure 110/70, pulse 80
MouthNo mucositis or thrush
NeckNo thyroid enlargement; no lymph node enlargement
CardiovascularRegular rhythm; no murmur
RespiratoryClear to auscultation bilaterally
AbdomenSoft; mild suprapubic tenderness; no masses
SkinDiffuse hair thinning; no rash
NeurologicalLight touch slightly reduced at the toes; vibration normal; gait normal
PsychiatricEngaged and humorous; not sedated

Problems

ProblemClinical statusVerificationCodeProvenance
Bleeding between periods and after intercourse, with heavier periods, a watery blood-stained discharge and a constant pelvic ache, for about five months; average pain 7 of 10 despite her opium tincture; a friable cervical mass found on examination and biopsied; cause not yet established at intakeresolvedconfirmed N93.8S — Synthetic presenting problem anchored to her documented final illness; superseded by the diagnosis at the second visit.
Iron deficiency anemia from chronic blood loss: hemoglobin 8.4 g/dL, mean cell volume 74 fL, ferritin 5 ng/mL, with tiredness and breathlessness on stairsactiveconfirmed D50.0S — Synthetic modern finding anchored to her documented final illness.
Adenocarcinoma of the endocervix, usual (HPV-associated) type, HPV 18 positive, FIGO 1843 stage IVB: a 5.2 cm tumor with left parametrial invasion, metastases to left pelvic and para-aortic lymph nodes, and bilateral lung metastases on MRI and PET-CT; PD-L1 combined positive score 5, mismatch repair proficient, HER2 1+; treated with palliative pelvic radiation for bleeding and carboplatin, paclitaxel and pembrolizumab, with specialist palliative care from diagnosisactiveconfirmed C53.0S — Synthetic modern diagnosis made at the second visit, anchored to her documented uterine cancer; the cervical site is a synthetic choice.
Cancer-related pelvic pain, nociceptive and visceral, from the cervical tumor and its left parametrial extensionactiveconfirmed G89.3S — Synthetic modern diagnosis made at the second visit.
Long-term prescribed opioid therapy: opium tincture for recurrent pelvic and abdominal pain for about two years, measured at times with a household spoon, converted at intake to measured oral morphine; no opioid use disorder on a DSM-5 assessment; naloxone suppliedactiveconfirmed Z79.891S — Synthetic modern history anchored to her documented laudanum and opium; not a claim about her real dosing.
Drug-induced constipation from long-acting morphine and ondansetron, a week after the first chemotherapy cycle: no bowel movement for five days, with bloating and cramping but passing wind, without vomiting; no bowel obstruction on examination; potassium and calcium normal; resolved with laxativesresolvedconfirmed K59.03S — Synthetic adverse drug effect; not a historical claim.

Assessment and Plan

Personalized prevention plan. A written copy was given to the patient. [S]

ServiceStatusDetail
Blood pressureCompleted today110/70 mmHg
Depression screeningCompleted todayPHQ-2 score 2; PHQ-9 9 five weeks ago
Tobacco useCompleted todayNever used tobacco
Unhealthy alcohol useCompleted todayAUDIT-C 0; no alcohol since diagnosis
Intimate partner violence screeningCompleted todayScreened in private; negative
HIV screeningUp to dateNonreactive at diagnosis
Hepatitis C screeningUp to dateAntibody nonreactive at diagnosis
Hepatitis B screening and vaccinationCompleted todaySurface antigen, core antibody and surface antibody all negative before treatment; CpG-adjuvanted vaccine dose 1 of 2 today
Pneumococcal vaccineCompleted todayPCV20 today for an immunocompromising condition
Zoster vaccineCompleted todayRecombinant zoster vaccine dose 1 of 2 today, recommended from 19 for immunocompromised adults
Tetanus, diphtheria, and pertussisCompleted todayTdap today
Influenza vaccineDueInactivated vaccine in the autumn, between cycles
COVID-19 vaccineDueCurrent vaccine in the autumn; recommended for immunocompromised adults
HPV vaccineNot indicatedAge 35 and already diagnosed with an HPV-related cancer
Live vaccinesNot indicatedContraindicated during chemotherapy and immunotherapy
Cervical cancer screeningNot indicatedUnder treatment for cervical cancer
Breast cancer screeningNot indicatedNot due before 40 at average risk
Diabetes and lipid screeningNot indicatedNot a priority during treatment; BMI 19.7
Contraception and pregnancyCompleted todayNot sexually active; told that chemotherapy and pembrolizumab can harm a pregnancy and to use contraception if that changes

Immunizations given today: Pneumococcal conjugate vaccine (PCV20); Recombinant zoster vaccine, dose 1 of 2; Tdap vaccine; Hepatitis B vaccine, CpG-adjuvanted (two-dose series), dose 1 of 2 [S]

Guideline basis: Palliative Care for Patients With Cancer: ASCO Guideline Update (Sanders JJ, et al. J Clin Oncol 2024;42:2336-2357) (2024); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Adult Immunization Schedule by Medical Condition and Other Indication (2026)

Follow-up: Fourteen-week review in three weeks, after the restaging CT. Next scheduled visit 1851-09-08: fourteen-week review: restaging CT, blood counts, iron and thyroid, pain, and a goals-of-care conversation. [S]

Advance Care Planning

Voluntary advance care planning discussion of about 30 minutes, with her consent, in the context of metastatic cancer. She named a health care agent and an alternate, recorded in the chart and not named here, and completed a health care proxy form. She wants treatment aimed at living longer while it lets her think and work, wants to be told the truth about her illness directly, and does not want her life prolonged by machines if she could no longer think clearly. Her wishes on resuscitation will be revisited after the restaging scan. A copy was sent to her oncology and palliative care teams. [S]